<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>CLP Blog</provider_name><provider_url>https://clpblog.citizen.org</provider_url><author_name>Allison Zieve</author_name><title>New FTC report on reverse-payment agreements between brand-name and generic drug companies - CLP Blog</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="yEYC6kgbB5"&gt;&lt;a href="https://clpblog.citizen.org/new-ftc-report-on-reverse-payment-agreements-between-brand-name-and-generic-drug-companies/"&gt;New FTC report on reverse-payment agreements between brand-name and generic drug companies&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://clpblog.citizen.org/new-ftc-report-on-reverse-payment-agreements-between-brand-name-and-generic-drug-companies/embed/#?secret=yEYC6kgbB5" width="600" height="338" title="&#x201C;New FTC report on reverse-payment agreements between brand-name and generic drug companies&#x201D; &#x2014; CLP Blog" data-secret="yEYC6kgbB5" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]&gt; */
&lt;/script&gt;
</html><description>&#xA0;&#xA0; For several years, the Federal Trade Commission has challenged under the antitrust laws so-called&#xA0; &#x201C;reverse-payment&#x201D; or &#x201C;pay-to-delay&#x201D; settlements. In such a settlement, a brand-name drug company pays a generic-drug company not to sell a generic equivalent of a drug, thus allowing the brand-name to maintain an exclusive market at a high price for years [...]</description></oembed>
